Latest news for Gensight Biologics (OTC:GSGTF) Stock

Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group's focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Biotech

News

Penny Stocks

Offerings

Small Cap

IPOs

General

ACAD

ADMA

ADTX

AFIB

ALZN

ATNX

AUPH

AVNS

AVTX

AYTU

AZRX

BGNE

BTAI

CALT

CMRX

CNCE

CRMD

CVRX

DICE

EIGR

ESPR

FBRX

GANX

GMDA

GSGTF

HOOK

INDP

INZY

ISEE

ITMR

KTTA

LIFE

MCRB

Morgan Stanley Capital Protected Notes for S&P 500 Index

MTEM

NPCE

OBSV

OYST

PHAR

PRCT

RDHL

REGN

RNAZ

SAGE

SBBP

SPRB

Syneos Health, Inc. - Class A Common Stock

SYNH

TBPH

TCRX

TXMD

TYRA

VCYT

XERS

ZNTL

ZYXI

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.

Scaling The Peaks

(Biotech Stocks Hitting 52-week Highs Sept. 14)

The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

AACAY

AAPL

AAVXF

ACLLF

AHCHY

AIMT

ALCO

ALLE

AMTBB

ANGPY

APRE

APTO

ARCAY

ARES

ARGX

ARVN

ASPU

ASUUY

ATLKY

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

BANF

BOCH

BOLD

BUKS

CBRE

CBSH

CCLAF

CDMO

CRSS

CRUS

CSTM

CTBI

CUBA

DCPH

DEWY

DFCO

DPMLF

EDTXF

EFIN

EGRN

ENIA

ERRFY

ESLT

FELE

FLXN

FORM

FORTY

FSUGY

FTSV

GLDD

GOLF

GOSS

GSBD

HBAN

ICBK

IDEXF

IDEXY

IMKTA

IMMU

IMPUF

IMPUY

INCY

INSG

ITOCF

IVSXF

JADSF

JPRRF

KKKUF

KRMD

Stocks That Hit 52-Week Highs On Wednesday

GENSIGHT BIOLOGICS SA by Gensight Biologics SA

Gensight Biologics SA

Earnings

Earnings Beats

Earnings Misses

TE Connectivity Q1 2025 Adj. EPS $1.95 Beats $1.89 Estimate, Sales $3.836B Miss $3.905B Estimate

Certain law enforcement officials from California are seemingly impressed by Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) vehicles customized for police use by vehicle customizer Unplugged Performance. 
What Happened: Unplugged Performance in December held an event where law enforcement executives tried out the <a href="https://www.benzinga.com/top-stories/24/04/38257550/tesla-model-y-enters-anaheim-police-fleet-in-new-pilot-initiative">Tesla vehicles upgraded</a> by the company. 
The officials drove the Tesla vehicles around at an EVOC facility and also compared it to a Ford Explorer PIU (Police Interceptor Utility SUV) with some concluding that the Tesla is way more fun to drive than the Explorer. 
Feedback From Law Enforcement Officials:&nbsp;&#8220;I think the difference between the two vehicles is just absolutely staggering. So after doing roughly you know 20/30 laps in the Tesla handling that course and then I jumped in the Explorer, did the same course, and I can tell you right off the bat I pretty much didn&#8217;t want to be in the Explorer anymore,&#8221; one of the officers said in the video premiered on YouTube on Tuesday.
An official, who had previously never driven a Tesla, said that the experience changed his perspective positively.
&#8220;I&#8217;d never driven one until today and I have a different mindset here at 2 p.m. than I did this morning at 6 a.m.,&#8221; he said. 
Why It Matters: Unplugged Performance,<a href="https://www.benzinga.com/news/24/06/39240046/tesla-customizer-upfits-cybertruck-for-the-police-forces-elon-musk-thinks-its-cool"> based out of California</a>, has been enhancing Tesla vehicles since 2013 and is located next to the company's design studio. 
According to Unplugged Performance, an upgraded Model Y AWD Patrol vehicle will cost $92,580, including upfitting costs, marginally higher than the Ford Police Interceptor Utility AWD Hybrid priced at $89,600. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Can UP.FIT Tesla Vehicles Handle Police Duty? This EVOC Trial Might Change Your Mind." width="500" height="281" src="https://www.youtube.com/embed/jaRObrWstTc?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43090016/which-evs-might-lose-7500-ev-tax-credit-under-trump-administration" target="_blank" rel="noreferrer noopener">Here Are The EVs Which Could Lose $7,500 EV Tax Credit Under Trump Administration</a></li>
</ul>
Image via Shutterstock

Tech

TSLA

California Law Enforcement Impressed By Upfitted Tesla Police Vehicle: 'I Pretty Much Didn't Want To Be In The Explorer Anymore'

Headquartered in San Mateo, Calif., QuSecure is a privately held company founded in 2019.&nbsp;

Accenture Reveals Strategic Investment, Through Accenture Ventures, In Post-quantum Cybersecurity Company QuSecure; Terms Not Disclosed

Barclays analyst Benjamin Theurer upgrades Hormel Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRL#NYSE">HRL</a>) from Equal-Weight to Overweight and raises the price target from $35 to $36.

Upgrades

Price Target

Analyst Ratings

Barclays Upgrades Hormel Foods to Overweight, Raises Price Target to $36

Barclays analyst Kannan Venkateshwar upgrades Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from Underweight to Equal-Weight and raises the price target from $715 to $900.

NFLX

Barclays Upgrades Netflix to Equal-Weight, Raises Price Target to $900

German sportswear brand Adidas AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ADDYY#OTC">ADDYY</a>) has released its <a target="_blank" href="https://www.adidas-group.com/en/media/press-releases/adidas-finishes-successful-year-with-better-than-expected-fourth-quarter-results" rel="noreferrer noopener">preliminary </a>results for the fourth quarter of 2024.
The company&#8217;s revenue increased by 19% in currency-neutral terms, with a 24% rise in euro terms, totaling 5.97 billion euros (~$6.24 billion). Excluding <a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38511886/adidas-puts-yeezy-history-behind-rides-fashion-high-with-samba-and-gazelle-shoes" rel="noreferrer noopener">Yeezy sales from both years</a>, currency-neutral growth was 18%.
Additionally, the company saw a notable improvement in its gross margin, which grew by 520 basis points to 49.8%, up from 44.6% in 2023.
Fourth-quarter operating profit reached 57 million euros, reversing the 377 million euros loss recorded in the same quarter last year.
Adidas also posted strong growth for the full year 2024. Its revenue climbed 12% on a currency-neutral basis, reaching 23.68 billion euros. When excluding Yeezy sales, the company saw a 13% increase in currency-neutral revenues.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/01/43098100/costco-workers-vote-to-strike-over-fair-contract-demands" rel="noreferrer noopener">Costco Workers Vote To Strike Over Fair Contract Demands</a>
The gross margin for the year improved by 330 basis points, reaching 50.8%. Operating profit surged by over 1 billion euros, rising from 268 million euros in 2023 to 1.34 billion euros in 2024.
&#8220;We clearly see that consumers&#8217; and retailers&#8217; interest in our products is growing across both Lifestyle and Performance. Strong growth across all regions and divisions proves the good job our teams are doing across regions and functions,&#8221; said CEO Bjørn Gulden.
&#8220;We also feel good about the future, and we see potential to increase our market share in all markets. There is a lot of macroeconomic uncertainty right now, but we clearly have the goal to again grow double-digit with the adidas brand and use that growth to continue to improve our operating profit and make further progress towards our 10% margin target.&#8221;
Price Action: ADDYY shares closed higher by 6.59% at $132.22 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43108106/volkswagen-warns-of-tariffs-impact-on-us-consumers" target="_blank" rel="noreferrer noopener">Volkswagen &#8216;Concerned&#8217; Over Trump Tariffs: Will Automakers Pass Costs To US Consumers?</a></li>
</ul>
Image via Shutterstock.

Equities

Guidance

ADDYY

Adidas Sees Solid Gains In Q4, Looks To Expand Market Share

Barclays analyst Simon Coles downgrades STMicroelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) from Equal-Weight to Underweight.

Downgrades

Barclays Downgrades STMicroelectronics to Underweight

JP Morgan analyst Mark Murphy downgrades Paycor HCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYCR#NASDAQ">PYCR</a>) from Neutral to Underweight and raises the price target from $21 to $22.5.

PYCR

JP Morgan Downgrades Paycor HCM to Underweight, Raises Price Target to $22.5

JP Morgan analyst James Kirby initiates coverage on Sun Country Airlines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCY#NASDAQ">SNCY</a>) with a Overweight rating and announces Price Target of $23.

Initiation

SNCY

JP Morgan Initiates Coverage On Sun Country Airlines with Overweight Rating, Announces Price Target of $23

JP Morgan analyst DS Kim downgrades New Oriental Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) from Overweight to Neutral and lowers the price target from $85 to $50.

New Oriental Education & Technology Group

JP Morgan Downgrades New Oriental Education to Neutral, Lowers Price Target to $50

Tesla Inc. CEO Elon Musk cast doubt Wednesday on the ambitious $500 billion Project Stargate, hours after its announcement, claiming lead investor SoftBank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) has &#8220;well under $10B secured.&#8221;
What Happened: The project, unveiled Tuesday at a White House briefing in the presence of President Donald Trump, represents a joint venture between OpenAI, SoftBank, and Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) to establish massive <a href="https://www.benzinga.com/25/01/43111153/nvidia-and-ai-stock-rises-as-trump-announces-500-billion-stargate-ai-infrastructure-venture">artificial intelligence infrastructure across the United States</a>. 
&#8220;They don't actually have the money,&#8221; Musk said.
&#8220;SoftBank has well under $10B secured. I have that on good authority.&#8221;
During the briefing, Oracle co-founder Larry Ellison highlighted the project&#8217;s healthcare applications, including an AI-driven system capable of delivering personalized cancer vaccines within 48 hours. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">SoftBank has well under $10B secured. I have that on good authority.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1881944244480565497?ref_src=twsrc%5Etfw">January 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/general/biotech/25/01/43119814/google-parent-owned-startup-to-launch-ai-designed-drug-trials-by-year-end-partnering-with-eli-lilly-and-novartis-to-tackle-major-diseases">Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases</a>
Why It Matters: The initiative plans to deploy an initial $100 billion immediately, starting with a 500,000-square-foot data center in Abilene, Texas. Nine additional facilities are planned, with potential expansion to 20 locations.
Technology partners Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), and Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) saw their stocks climb on the news. NVIDIA rose 3.95% to $143.15, while Arm jumped 8.94% to $162.60.
OpenAI, maintaining operational responsibility while SoftBank leads financial aspects, stated the project &#8220;will secure American leadership in AI&#8221; and &#8220;create hundreds of thousands of American jobs.&#8221; SoftBank&#8217;s Masayoshi Son will serve as chairman.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/43119464/netflix-raises-prices-16-peter-schiff-warns-of-escalating-inflation-risks-ahead-of-trump-policies">Netflix Raises Prices 16%, Peter Schiff Warns Of Escalating Inflation Risks Ahead Of Trump Policies</a></li>
</ul>
Image via Wikimedia Commons
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

MSFT

NVDA

ORCL

SFTBF

SFTBY

Elon Musk Says Project Stargate Doesn't 'Actually Have The Money' After Trump Announces $500 Billion AI Investment Led By SoftBank, Oracle And OpenAI

Jefferies analyst Dennis Ding upgrades Crinetics Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>) from Hold to Buy and announces $55 price target.

CRNX

Jefferies Upgrades Crinetics Pharmaceuticals to Buy, Announces $55 Price Target

Canaccord Genuity analyst Caitlin Burrows initiates coverage on Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) with a Buy rating and announces Price Target of $24.

OFIX

Canaccord Genuity Initiates Coverage On Orthofix Medical with Buy Rating, Announces Price Target of $24

Canaccord Genuity analyst Maria Ripps upgrades Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from Hold to Buy and raises the price target from $940 to $1150.

Canaccord Genuity Upgrades Netflix to Buy, Raises Price Target to $1150

HUIZ

Huize Stated That It Served Over 1.3 Million Families With More Than 12 Million Insurance Policies Facilitated And Assisted In Processing 160,800 Insurance Claims (+74.7% YoY) In 2024

Shares of Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) rose sharply in today's pre-market trading as the company reported stronger-than-expected <a href="https://www.benzinga.com/news/earnings/25/01/43114866/netflix-q4-earnings-record-subscribers-nfl-squid-game-push-past-highest-expectations">fourth-quarter financial results</a>.
Netflix reported it added 18.91 million paid subscribers in the fiscal quarter, up 15.9% year-over-year. The company said it sees full-year revenue of $43.5 billion to $44.5 billion, up $0.5 billion from the company's previous range
Netflix shares jumped 14.6% to $996.60 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>ImmunoPrecise Antibodies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPA#NASDAQ">IPA</a>) gained 58.8% to $0.7833 in pre-market trading. ImmunoPrecise Antibodies recently launched its AI-powered pipeline of both optimized and new therapeutics.</li>
<li>New Era Helium, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEHC#NASDAQ">NEHC</a>) rose 42% to $3.89 in pre-market trading. New Era Helium recently announced a joint venture with Sharon AI to construct and develop a 250MW net-zero energy data center..</li>
<li>Cardio Diagnostics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) rose 40.2% to $0.8520 in pre-market trading after jumping around 15% on Tuesday.</li>
<li>Asset Entities Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) gained 25.7% to $1.13 in pre-market trading after jumping 94% on Tuesday.</li>
<li>U.S. Energy Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEG#NASDAQ">USEG</a>) gained 21.5% to $4.61 in pre-market trading after surging 63% on Tuesday.</li>
<li>Metagenomi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) gained 20.2% to $3.27 in pre-market trading following a 4% gain on Tuesday.</li>
<li>Tempus AI, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) gained 14.7% to $54.65 in pre-market trading. Tempus AI shares jumped over 35% on Tuesday after Nancy Pelosi disclosed the purchase of 50 Jan 2026 call options.</li>
<li>CareCloud, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) gained 13.3% to $3.50 in pre-market trading after surging over 10% on Tuesday.</li>
<li>Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) gained 13.2% to $29.63 in pre-market trading after gaining around 7% on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Associated Capital Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AC#NYSE">AC</a>) fell 43.7% to $20.00 in pre-market trading. Associated Capital recently reported estimated fourth quarter and full year results</li>
<li>Star Fashion Culture Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STFS#NASDAQ">STFS</a>) shares fell 20.7% to $10.72 in pre-market trading after dipping around 9% on Tuesday.</li>
<li>HUB Cyber Security Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUBC#NASDAQ">HUBC</a>) fell 19.5% to $0.68 in pre-market trading after the company announced the receipt of a Staff Delisting Notice.</li>
<li>Lisata Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTA#NASDAQ">LSTA</a>) shares dipped 17.4% to $3.22 in pre-market trading after gaining 5% on Tuesday.</li>
<li>Septerna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) fell 14.4% to $16.01 in pre-market trading after gaining more than 10% on Tuesday.</li>
<li>Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares tumbled 13.1% to $0.8949 in pre-market trading after the company announced exercise of warrants and issuance of new warrants in a private placement for $3.7 million gross proceeds priced at-the-market.</li>
<li>Dogwood Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) shares fell 13% to $2.74 in pre-market trading. Dogwood Therapeutics shares jumped 68% on Tuesday after the company announced patient dosing for its Phase 2b trial evaluating halneuron will commence in Q1 2025.</li>
<li>AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) declined 12.3% to $14.81 in pre-market trading after gaining over 6% on Tuesday.</li>
<li>InMed Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INM#NASDAQ">INM</a>) fell 11.8% to $4.45 in today's pre-market trading. InMed Pharmaceuticals recently announced that INM-901 reduced Alzheimer &#8216;s-related inflammation in a preclinical study.</li>
<li>Marine Products Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPX#NYSE">MPX</a>) dipped 11.3% to $8.04 in pre-market trading. Marine Products will release its financial results for the fourth quarter on Thursday, Jan. 30, before the market opens.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>

Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Comments

Gensight Biologics

News

Latest news for Gensight Biologics (OTC:GSGTF) Stock

Wednesday, September 15, 2021

Wednesday, December 11, 2019

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga